PARSIPPANY, N.J., Oct. 30, 2014 /PRNewswire/ -- PDI, Inc. (Nasdaq: PDII), a leading healthcare commercialization company, has responded to the letter dated October 29, 2014 from Digirad Corporation regarding Digirad's willingness to offer to acquire PDI by indicating that PDI is not for sale and does not view Digirad's letter to be a meaningful offer to acquire PDI.
The full text of the letter which reinforces the view of PDI and its board of directors is as follows:
October 29, 2014
Matthew G. Molchan
President and Chief Executive Officer
Digirad Corporation
1048 Industrial Court, Suite E
Suwanee, GA 30024
Dear Mr. Molchan:
I am in receipt of your letter dated October 29, 2014 regarding Digirad's willingness to offer to acquire PDI, Inc. PDI's Board of Directors has reviewed and considered your letter. PDI's Board of Directors does not consider PDI for sale and does not view your letter to be a meaningful offer to acquire PDI.
Sincerely,
Gerald P. Belle
Chairman of the Board
PDI, Inc.
About PDI, Inc.
PDI is a leading healthcare commercialization company providing superior go-to-market strategy and execution to established and emerging healthcare companies through its three core business units. The company's Sales Services business unit (CSO) is a leading provider of outsourced pharmaceutical, medical device and diagnostics sales teams. PDI's Product Commercialization Services, including Interpace Diagnostics, provides full product commercialization and is working to develop and commercialize molecular diagnostic tests leveraging the latest technology and personalized medicine for better patient diagnosis and management. Its Marketing Services division is a pioneer in insight-driven digital communication services and integrated multichannel message delivery.
For more information about PDI, Inc. or Interpace Diagnostics, please visit http://www.pdi-inc.com and www.interpacediagnostics.com.
Logo - http://photos.prnewswire.com/prnh/20140114/NY45872LOGO
SOURCE PDI, Inc.
